X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 16.5 37.6 43.9% View Chart
P/BV x 17.8 6.1 291.8% View Chart
Dividend Yield % 0.6 0.7 87.4%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-18
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8771,142 76.8%   
Low Rs424533 79.4%   
Sales per share (Unadj.) Rs223.4146.6 152.4%  
Earnings per share (Unadj.) Rs31.133.0 94.0%  
Cash flow per share (Unadj.) Rs40.338.4 104.9%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.81.2 64.4%  
Book value per share (Unadj.) Rs219.5222.8 98.5%  
Shares outstanding (eoy) m33.07265.47 12.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.95.7 50.9%   
Avg P/E ratio x20.925.3 82.6%  
P/CF ratio (eoy) x16.121.8 74.0%  
Price / Book Value ratio x3.03.8 78.8%  
Dividend payout %16.130.3 53.2%   
Avg Mkt Cap Rs m21,504222,318 9.7%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m1,1284,561 24.7%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m7,38938,915 19.0%  
Other income Rs m1671,134 14.7%   
Total revenues Rs m7,55640,049 18.9%   
Gross profit Rs m1,79312,617 14.2%  
Depreciation Rs m3041,425 21.4%   
Interest Rs m36613 2,753.4%   
Profit before tax Rs m1,29012,313 10.5%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3093,543 8.7%   
Profit after tax Rs m1,0278,770 11.7%  
Gross profit margin %24.332.4 74.9%  
Effective tax rate %23.928.8 83.2%   
Net profit margin %13.922.5 61.7%  
BALANCE SHEET DATA
Current assets Rs m3,68145,351 8.1%   
Current liabilities Rs m3,1236,507 48.0%   
Net working cap to sales %7.699.8 7.6%  
Current ratio x1.27.0 16.9%  
Inventory Days Days89127 70.6%  
Debtors Days Days5995 61.7%  
Net fixed assets Rs m7,68521,160 36.3%   
Share capital Rs m331531 62.3%   
"Free" reserves Rs m6,67058,625 11.4%   
Net worth Rs m7,25959,156 12.3%   
Long term debt Rs m9550-   
Total assets Rs m11,95767,832 17.6%  
Interest coverage x4.5926.8 0.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 107.7%   
Return on assets %11.712.9 90.0%  
Return on equity %14.214.8 95.5%  
Return on capital %20.720.8 99.5%  
Exports to sales %39.40-   
Imports to sales %5.721.8 26.1%   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m4218,485 5.0%   
Fx inflow Rs m3,44532,359 10.6%   
Fx outflow Rs m7039,042 7.8%   
Net fx Rs m2,74323,317 11.8%   
CASH FLOW
From Operations Rs m1,4407,759 18.6%  
From Investments Rs m-1,089-4,783 22.8%  
From Financial Activity Rs m-353-3,142 11.2%  
Net Cashflow Rs m-1-166 0.9%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  BIOCON LTD  UNICHEM LAB  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 24, 2018 12:37 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS